LAURA MCFADDEN: Open Payments
NPI 1386161800 · SAINT JOSEPH, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,445 in 77 payments from 34 companies in 2025. Trend: 2023 $1,036 · 2024 $2,245 · 2025 $1,445
Food & beverage: $1,445
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $208 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $162 |
| ABBVIE INC. | 4 | $94 |
| Astellas Pharma US Inc | 4 | $87 |
| Merck Sharp & Dohme LLC | 4 | $78 |
| Gilead Sciences, Inc. | 3 | $56 |
| GlaxoSmithKline, LLC. | 3 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $51 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| Ardelyx, Inc. | 2 | $40 |
Products named: CAPLYTA, ENHERTU, KEYTRUDA, Veozah, Trodelvy, LYNPARZA, INGREZZA, VENCLEXTA.
Industry payments across MO — which companies pay providers there.
